国际肿瘤学杂志

国际肿瘤学杂志 ›› 2019, Vol. 46 ›› Issue (10): 631-633.doi: 10.3760/cma.j.issn.1673-422X.2019.10.014

• 综述 • 上一篇    下一篇

卡博替尼治疗转移性肾细胞癌的新进展

梅彦侠1,赵一舟2   

  1. 1浙江大学医学院附属邵逸夫医院科教科，杭州310000； 2浙江大学医学院附属第一医院科教科，杭州310000

  • 出版日期:2019-10-08 发布日期:2019-12-22
  • 通讯作者: 梅彦侠，Email： meiyanxia.123@163.com E-mail:meiyanxia.123@163.com

New progress of cabozantinib in the treatment of metastatic renal cell carcinoma

Mei Yanxia1, Zhao Yizhou2   

  1. 1Department of Science and Education, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China; 2Department of Science and Education, First Affilicated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China

  • Online:2019-10-08 Published:2019-12-22
  • Contact: Mei Yanxia, Email: meiyanxia.123@163.com E-mail:meiyanxia.123@163.com

PDF

261

摘要：

肾细胞癌是肾脏最常见的恶性肿瘤，具有早期诊断难、对放化疗不敏感及预后差等特点。局限期的治疗手段是手术切除，晚期主要以免疫和靶向治疗为主。近年来随着对分子靶向治疗研究的不断深入，诸多靶向药物相继上市。卡博替尼已被批准用于转移性肾细胞癌一线及二线的治疗药物，其安全性和有效性均在Ⅱ～Ⅲ期临床试验中得到充分的证明。

关键词:

癌, 肾细胞, 临床试验, 卡博替尼

Abstract:

Renal cell carcinoma (RCC), the most common form of kidney cancer, is characteristic by difficult in diagnosis at an early stage, insensitivity to chemoradiotherapy, poor prognosis, etc.. Localized RCC is treated by surgery while advanced RCC is mainly treated by immunotherapy and targeted therapy. With the ongoing in-depth researches on targeted therapy in recent years, plenty of targeted drugs come into the market in succession. Cabozantinib has been approved for the treatment of advanced RCC in the first/second line setting. It′s safety profile and efficiency have been demonstrated in Ⅱ-Ⅲ clinical trials.

Key words:

Carcinoma, renal cell, Clinical trial, Cabozantinib ,